Anti-diabetic and anti-Alzheimer's disease activities of Angelica decursiva

Arch Pharm Res. 2015 Dec;38(12):2216-27. doi: 10.1007/s12272-015-0629-0. Epub 2015 Jul 8.

Abstract

Diabetes mellitus (DM) and Alzheimer's disease (AD) constitute two global health issues. DM is an ever-increasing epidemic affecting millions of elderly people worldwide, causing major repercussions on patients' daily lives, mostly due to chronic complications. Complications from DM can affect the brain, thereby characterizing DM as a risk factor for AD. In the present study, we examined the inhibitory activity of methanol extracts of different parts of 12 Angelica species against α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). The methanol extract of Angelica decursiva exhibited the highest inhibitory activities against α-glucosidase, PTP1B, AChE, and BChE and so was selected for further investigation. Repeated column chromatography based on bioactivity-guided fractionation yielded seven compounds (1-7). Among these compounds, nodakenin (1), nodakenetin (2), umbelliferone (3), cis-3'-acetyl-4'-angeloylkhellactone (4), 3'(R)-O-acetyl-4'(S)-O-tigloylkhellactone (5), isorutarine (6), and para-hydroxybenzoic acid (7) exhibited potent inhibitory activities against α-glucosidase, PTP1B, rat lens aldose reductase (RLAR), AChE, BChE, and β-site amyloid precursor protein cleaving enzyme 1 (BACE1). Our results clearly indicate the potential inhibition of α-glucosidase, PTP1B, RLAR, AChE, BChE, and BACE1 by A. decursiva as well as its isolated constituents, which could be further explored to develop therapeutic modalities for the treatment of DM and AD.

Keywords: Alzheimer’s disease; Angelica decursiva; Cholinesterase; Coumarin; Protein tyrosine phosphatase 1B; Rat lens aldose reductase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / enzymology
  • Amyloid Precursor Protein Secretases / antagonists & inhibitors
  • Amyloid Precursor Protein Secretases / metabolism
  • Angelica*
  • Animals
  • Aspartic Acid Endopeptidases / antagonists & inhibitors
  • Aspartic Acid Endopeptidases / metabolism
  • Cholinesterase Inhibitors / isolation & purification*
  • Cholinesterase Inhibitors / pharmacology
  • Cholinesterase Inhibitors / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Diabetes Mellitus* / metabolism
  • Humans
  • Hypoglycemic Agents / isolation & purification*
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Plant Extracts / isolation & purification*
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • alpha-Glucosidases / metabolism

Substances

  • Cholinesterase Inhibitors
  • Hypoglycemic Agents
  • Plant Extracts
  • PTPN1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • alpha-Glucosidases
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases
  • BACE1 protein, human